Highlights d 50% HTT mRNA is localized in cell nucleus d HTT mRNA nuclear localization is limited to neuronal cells d Nuclear HTT mRNA is more stable than cytoplasmic d Nuclear HTT mRNA resists silencing by therapeutic oligonucleotides SUMMARY Huntington's disease (HD) is a monogenic neurodegenerative disorder representing an ideal candidate for gene silencing with oligonucleotide therapeutics (i.e., antisense oligonucleotides [ASOs] and small interfering RNAs [siRNAs]). Using an ultra-sensitive branched fluorescence in situ hybridization (FISH) method, we show that $50% of wild-type HTT mRNA localizes to the nucleus and that its nuclear localization is observed only in neuronal cells. In mouse brain sections, we detect Htt mRNA predominantly in neurons, with a wide range of Htt foci observed per cell. We further show that siRNAs and ASOs efficiently eliminate cytoplasmic HTT mRNA and HTT protein, but only ASOs induce a partial but significant reduction of nuclear HTT mRNA. We speculate that, like other mRNAs, HTT mRNA subcellular localization might play a role in important neuronal regulatory mechanisms.
In Brief
Huntington's disease (HD) is a monogenic neurodegenerative disorder representing an ideal candidate for gene silencing with oligonucleotide therapeutics. Didiot et al. examine the subcellular localization of HTT mRNA in non-neuronal and neuronal cells and the efficiency of oligonucleotide therapeutics on HTT mRNA subcellular fractions.
INTRODUCTION
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion within exon 1 of the coding region of the huntingtin gene (The Huntington's Disease Collaborative Research Group, 1993) . The monogenic nature of HD makes it an ideal candidate for gene silencing with oligonucleotide therapeutics, such as antisense oligonucleotides (ASOs) and short interfering RNAs (siRNAs), which are both involved in post-transcriptional gene silencing by reducing the target mRNA levels (for review, Crooke et al., 2018) . siRNAs induce mRNA degradation by loading into the RNA-induced silencing complex (RISC) in the cytoplasm, and ASOs promote mRNA degradation via RNase H in both the nucleus and the cytoplasm.
In the central dogma of cellular biology, the mRNAs are predominantly localized in the cytoplasm in mammalian cells.
Therefore, both classes of therapeutics are highly efficient at silencing mRNA expression, presumably due to the cytoplasmic localization of mRNA. When studying HTT mRNA silencing in different cell types, we observed that siRNA treatment fully silenced HTT in HeLa cells (>95%) but only reduced Htt by 50%-70% in mouse primary neurons (Alterman et al., 2015) . To understand the reason(s) behind this discrepancy in the degree of silencing in different cell types, we wanted to carefully visualize the cellular distribution of Htt mRNA in individual cells. We hypothesized that the differences in silencing efficacy were due to a difference in cellular localization of Htt mRNA between cell types.
In this study, we used a highly sensitive, branched fluorescence in situ hybridization (FISH) technology-RNAscope (Wang et al., 2012) -and confocal microscopy to observe and quantify the intracellular distribution of HTT mRNA at high resolution in single cells. We found that a significant fraction of HTT mRNA localizes to the nucleus of neuronal cells, but not non-neuronal cells. This cellular localization of HTT mRNA affects its silencing by therapeutic oligonucleotides both in vitro and in vivo: siRNAs and ASOs nearly eliminated cytoplasmic HTT mRNA and only ASOs partially reduced nuclear HTT mRNA levels. Our findings reveal a new parameter for consideration in our understanding of the role of HTT mRNA in neuronal regulatory mechanisms and oligonucleotide therapeutic development.
RESULTS

Branched FISH Technology Enables Precise In Situ
Detection of Spliced Htt mRNA Previously, CAG-specific probes have been used as a proxy for HTT mRNA detection (de Mezer et al., 2011; Urbanek et al., 2017) . However, we observed intense CAG FISH staining throughout the nucleus and cytoplasm, and a very low fraction of the CAG-FISH signal co-localized with the FISH signal using an HTT mRNA-specific probe set (Figures S1A and S1B). Thus, we implemented and validated a highly sensitive and specific branched FISH technology to detect Htt mRNA.
To ensure the specific detection of Htt mRNA by the FISH assay, we developed a panel of probes that target different regions of Htt mRNA and independent targets and used the following controls (Table S1; Figure S1 ): (1) co-targeting of Htt mRNA and CAG repeat (Figures S1A-S1D); (2) co-targeting the same Htt mRNA region (exons 27-35 [E27-35] ) in two different fluorescent channels (488 and 570 nm; Figures S1E-S1H); (3) co-targeting of two different regions of Htt mRNA (E1-7 and E27-35; Figures S1I-S1L); (4) co-targeting exonic (E27-35) and intronic (I61) regions of Htt mRNA (Figures S1M and S1N); and (5) co-targeting Htt mRNA and Herc2 mRNA (Figures S1O and S1P). To accurately estimate the number of mRNA foci per cell and ensure that intracellular distribution (nucleus versus cytoplasm) does not affect mRNA quantification, we quantified mRNA foci in three dimensions throughout the volume of each cell (see STAR Methods for details).
We observed up to 70% and 80% of FISH foci co-localization using probe sets that target similar or different regions of the Htt mRNA (Figures S1F and S1J) and no co-localization of Htt mRNA foci with Herc2 mRNA foci ( Figure S1P ). Background co-localization (calculated by rotating one channel 180 ) did not exceed 1% in most samples (Figures S1G, S1H, S1K, and S1L). The exception was the CAG-specific probe set, which resulted in $10% background co-localization, which is expected for probes that stain hundreds of foci per cell (Figures S1C and S1D). In addition, we observed that the majority of nuclear Htt mRNA foci localized in the nucleus appeared to be spliced (Figures S1M and S1N).
More Than 50% of Htt mRNA Is Localized to the Nucleus in Mouse Primary Neurons We assessed the intracellular distribution of Htt and control mRNAs in mouse primary cortical neurons . Precise quantification of mRNA foci by FISH showed $200 ActB, $25 Ppib, $30 Hprt, $37 Herc2, and $20 Htt foci per cell (Figures S2A and S2B) . Whereas most housekeeping mRNAs localized primarily in the cytoplasm (90% Ppib, $80% ActB, and $80% Hprt), 60% of Htt mRNA localized in the nucleus. The nuclear enrichment of Htt mRNA was not an artifact of mRNA length; we observed only 40% nuclear localization of Herc2 mRNA, which is longer than Htt mRNA (Table S1 ). As expected, the long non-coding RNAs (lncRNAs) Neat1 and Malat1 were only detected in the nucleus (Figures S2A and S2C) . To confirm Htt mRNA localization patterns observed by FISH and ensure that the probe hybridization is similar in nucleus and cytoplasm, we performed RT-qPCR to quantify nuclear and cytoplasmic ActB, Herc2, and Htt mRNA fractions isolated from primary neurons. The data showed that Htt mRNA is significantly more enriched in the nuclear fraction than ActB or Herc2 mRNA (respectively, ***p < 0.001 and *p < 0.05; Figures S2D  and S2E) . Thus, Htt mRNA shows an unusual enrichment in the nuclei of mouse primary neurons.
To determine whether the non-dividing characteristic of neurons affects Htt mRNA subcellular localization, we assessed mRNA distribution in dividing cells of neuronal origin (Neuro2a cells; Figure S2F ). Precise transcript quantification showed an average of $30 Htt, $115 Ppib, $75 Hprt, and $27 Herc2 mRNA foci per cell ( Figure S2G ). Whereas the control Hprt, Ppib, and Herc2 mRNA foci were all predominantly cytoplasmic (90%, 71%, and 64%), most Htt mRNA foci were nuclear (68%). As expected, almost all Neat1 lncRNA foci were nuclear (95%; Figures S2G and S2H ). Thus, nuclear enrichment of Htt mRNA is observed in both dividing and non-dividing cells of neuronal origin.
Htt mRNA Nuclear Localization Is Specific to Cells of Neuronal Origin
To determine the effect of cell type on Htt mRNA localization, we compared Htt mRNA distribution in non-neuronal cells (i.e., HeLa, human primary fibroblasts, and mouse primary fibroblasts) to that observed in cells of neuronal origin (i.e., mouse Neuro2a cells, cortical primary neurons, and mouse brain tissue). Whereas $50% of Htt mRNA foci localized to the nucleus in neuronal cells, only 10%-20% of Htt mRNA foci were nuclear in non-neuronal cells ( Figures  1A-1C ). These findings agree with our observation that siRNA can completely silence Htt mRNA in HeLa cells, but not in primary neurons.
In both primary neurons and brain sections, we observed significant cell-to-cell variability in both Htt mRNA expression and subcellular localization. To evaluate Htt mRNA level and distinguish between neuronal and non-neuronal cells in the brain, we developed and optimized a dual FISH-immunofluorescence approach that allows simultaneous detection of mRNA and protein. NeuN and GFAP were, respectively, used as markers for neurons ( Figure 2 ) and glial cells ( Figure S3 ). Htt mRNA in the brain was almost entirely neuronal. Moreover, the number of Htt mRNA foci varied widely between neurons: undetectable in some neurons and as many as 60 foci in others (Figures 2A, 2B , S3A, and S3B). On average, we observed $17 Htt mRNA foci per cell, with $55% of foci in the nucleus ( Figures 2B, 2D , S3C, and S3D). These data quantitatively confirm the previous findings that Htt mRNA is predominantly expressed in neurons in vivo (http:// proteinatlas.org).
Human Fibroblast Reprogramming into Neuron-like
Cells Changes HTT mRNA Nuclear-Cytoplasmic Distribution Human adult fibroblasts, which express cytoplasmic Htt mRNA, can be reprogrammed directly into neuron-like cells by overexpressing miR-9 and miR-124 and several neuronal transcription factors (Richner et al., 2015; Tang et al., 2013) . We therefore tested whether trans-differentiation of fibroblasts into neuron-like cells affects HTT mRNA subcellular distribution ( Figure 3 ). Upon the induction of miR-9 and miR-124 expression ( Figure 3A) , cells gradually acquired a neuronal morphology characterized by reduction of the cytoplasm and the development of neuronal projections (Figure 3B) . Before trans-differentiation, $90% of HTT mRNA foci were cytoplasmic. In trans-differentiated neuron-like cells, $60% of HTT mRNA foci were nuclear ( Figures 3C-3E ). The change in the nuclear-cytoplasmic ratio is accompanied by a sharp decrease in the number of cytoplasmic foci, suggesting that the rate of nucleo-cytoplasmic export of Htt mRNA might differ in neuronal and non-neuronal cells. Thus, cell type, rather than origin, is crucial in defining HTT mRNA cellular localization.
Nuclear Htt mRNA Is More Stable than Cytoplasmic Htt mRNA Several cellular processes might contribute to nuclear retention of Htt mRNA in neuronal cells, including slow nuclear-cytoplasmic export or rapid cytoplasmic mRNA turnover. To determine the rate of Htt mRNA turnover, we blocked RNA polymerase II (Pol II)-mediated transcription and quantified mRNA levels at 2, 4, 6, 8, and 10 hr posttranscriptional inhibition ( Figures S4A-S4C ). Cytoplasmic Htt mRNA levels (4-hr half-life) decreased significantly faster than nuclear Htt mRNA (10-hr half-life; ****p < 0.0001; Figures S4A and S4B). By contrast, Herc2 mRNA turned over at the same rate in both nuclear and cytoplasmic fractions ($6-hr half-life; Figure S4C ). The cytoplasmic Htt and Herc2 mRNAs decreased at similar rates, and nuclear Htt mRNA decreased at a significantly slower rate than Herc2 mRNA (Figures S4B and S4C). Nuclear Htt mRNA Resists Silencing by Both ASOs and siRNAs Our findings suggest that the neuronal-specific nuclear enrichment of Htt mRNA could explain why siRNAs cannot fully silence Htt mRNA in neuronal cells. We therefore directly tested whether the subcellular localization of Htt mRNA affects its ability to be silenced by therapeutic oligonucleotides (Figures 4 and S4E-S4K).
Mouse primary neurons were treated for 7 days with either LNA GapmeR ASO targeting position 3,209 in Htt exon 23 (ASO HTT ) (Hung and Leeds, 2007) or chemically stabilized, hydrophobic siRNA targeting position 10,150 in Htt 3 0 UTR (siRNA HTT ) (Alterman et al., 2015) . Sequence and chemical composition of compounds used are shown in Table S2 . FISH analysis of treated neurons showed that both chol-siRNA HTT and DHA-siRNA HTT reduced cytoplasmic Htt mRNA foci by 90% ( Figures S4E  and S4H ), but not nuclear Htt mRNA foci. ASO HTT significantly reduced the number of cytoplasmic and nuclear Htt foci (by 80% and 40%; Figure S4E ). There was no major impact of both siRNAs and ASOs on Hprt and Herc2 mRNA foci level and localization ( Figures S4F and S4G ). siRNA and ASO cytotoxicity, measured using the alamar blue assay, showed that the primary neurons' viability was not altered by the treatment at the indicated concentrations ( Figure S4H ). To evaluate siRNAs' and ASOs' silencing efficiency, we measured the total cellular level of Htt mRNA using the QuantiGene assay. We observed 60% Htt mRNA silencing in cells treated with 0.15 mM ASO HTT or siRNA HTT (Figure S4K ), consistent with previous observations. At 1.25 mM concentration, ASO HTT reduced total Htt mRNA by $85%, whereas siRNA HTT only reduced total Htt mRNA by $75%, consistent with the possibility that siRNAs mostly silence cytoplasmic Htt mRNA and ASOs silence both nuclear and cytoplasmic Htt mRNA. Consistent with efficient silencing of cytoplasmic Htt mRNA, both therapeutic oligonucleotides significantly reduced HTT protein levels ( Figures S4I and S4J) .
We evaluated the impact of Htt mRNA subcellular distribution on oligonucleotide efficiency in vivo (Figure 4 ). When injected directly in mouse striatum, DHA-siRNAs induced efficient Htt mRNA silencing and had no measurable impact on neuronal integrity or innate immune activation (Nikan et al., 2016) . Mice were directly injected with 4 nmol DHA-siRNA NTC , DHA-siRNA HTT (Nikan et al., 2016) , ASO NTC , and ASO HTT (Hung and Leeds, 2007) in the right striatum (n = 3 animals per group; Figure 4A ). After 7 days, levels of nuclear and cytoplasmic Htt mRNA foci were assessed by FISH ( Figures 4B and 4C) . Consistent with the data obtained in vitro, we observed that DHA-siRNA HTT reduced cytoplasmic Htt mRNA foci by 95%, but not nuclear Htt mRNA foci. In contrast, ASO HTT significantly reduced the number of both cytoplasmic and nuclear Htt foci by 90% and 60%, respectively ( Figure 4D ). We did not detect any significant impact by either siRNA or ASO on Hprt and Herc2 mRNA foci level and localization ( Figures 4E and 4F) . 
DISCUSSION
The HD gene Htt is expressed throughout the body, but HD pathology is primarily limited to neuronal tissues. Using branched FISH, high-resolution confocal microscopy, and volumetric quantification of mRNA foci, we show that wild-type Htt mRNAs (with a normal number of CAG repeats) accumulate in the nucleus of neuronal cells, but not in non-neuronal cells. A similar Htt distribution pattern was demonstrated by the analysis of RNA sequencing (RNA-seq) datasets from human embryonic stem cell (HESC)-derived neurons (Blair et al., 2017;  Figure S3E ). The results showed that, relative to the total number of reads in each sample, Htt transcript is detected more often in the nuclear fraction than in the cytoplasmic fraction. These findings suggest that Htt mRNA processing, export, or stability is differentially regulated in neuronal cells both in vitro and in vivo.
Advances in oligonucleotide therapeutics have put effective treatments for HD within reach (Kordasiewicz et al., 2012; http://www.ionispharma.com) . Therapeutic oligonucleotides cause gene silencing by directing mRNA destruction, thereby preventing the expression of proteins involved in genetic disease. Whereas ASOs target mRNAs in the nucleus and cytoplasm, siRNAs primarily target mRNAs in the cytoplasm (this study and Castanotto et al., 2015) . We have found that ASOs partially but significantly reduce the nuclear fraction of Htt, and siRNAs do not silence nuclear Htt mRNA at the used concentrations used. Regardless of the oligonucleotide used, nuclear Htt mRNA is more resistant to silencing than cytoplasmic Htt mRNA. The resistance of nuclear Htt mRNA to silencing by oligonucleotides could be related to the increased stability or retention of nuclear Htt mRNA compared to cytoplasmic Htt mRNA. Future studies are needed to understand the compartmental efficiency of various oligonucleotides on wild-type and mutant Htt and for the development and optimization of therapeutics to treat HD and other neurodegenerative diseases.
The investigation of Htt mRNA distribution in brain sections revealed a high degree of variability in levels of Htt mRNA expression between different cell types (neurons versus glia) and within the same cell types. In general, neurons express significantly more Htt mRNA than glia. Similarly, detection of HTT mRNA in wild-type human brain by immunohistochemistry showed higher level of HTT mRNA in neurons than in glia (Landwehrmeyer et al., 1995) . These data are consistent with data from RNA-seq datasets performed on various cell population of mouse cerebral cortex and suggest Htt mRNA is predominantly expressed in neurons compared to glia  Figure S3F ). Interestingly, as previously described, we also observed a substantial variability of Htt mRNA level between individual neurons, with neurons not expressing Htt mRNA and neurons expressing as many as 60 copies per cell . Several studies have demonstrated that the cell to cell variability is a biological phenomenon and could play critical roles in determining biologically and clinically significant phenotypes (for review, Patange et al., 2018) . HTT mRNA subcellular distribution, as well as expression variability, may provide valuable information about HTT function in neuronal regulatory mechanisms.
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Summary and Conclusion
Using branched FISH, we localize and quantify wild-type Htt mRNA (non-expanded CAG repeat) in different cell types and evaluate the differential silencing efficiency of ASOs and siRNAs on nuclear versus cytoplasmic Htt mRNA. We show that more Htt mRNA is nuclear in neuronal cells compared to non-neuronal cells. Furthermore, we show that siRNAs and ASOs differentially silence nuclear and cytoplasmic Htt mRNA. This is the first detailed observation of a clear change in Htt mRNA intracellular localization based on cellular identity and the first investigation of the differential subcellular efficacy of different oligonucleotide therapies. These results provide insight into the characteristics of Htt mRNA, incite future investigation into the subcellular distribution of mutant Htt mRNA, and identify a new aspect for consideration in the development of future oligonucleotide therapeutics targeting HTT mRNA.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice and Ethic Statements
Female wild-type FVB/NJ mice were purchased from The Jackson Laboratory and maintained in a specific pathogen-free facility. All procedures were performed in accordance with the National Institutes of Health Guideline for Laboratory Animals (including the timed pregnant mice used to obtain primary neurons) and were approved by the University of Massachusetts Medical School IACUC (Protocol #A2411).
Human Primary Cells
Adult dermal fibroblasts from healthy control were acquired from the Coriell Institute for Medical Research. Therefore, in regard to deidentified skin fibroblasts samples, we do not have access to the master list to reidentify subjects. This activity is not considered to meet federal definitions under the jurisdiction of an institutional review board and is thus exempt from the definition of human subject.
METHOD DETAILS
Cell Culture HeLa and Neuroblastoma 2a (Neuro2a) cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Cellgro #10-013CV) supplemented with 10% fetal bovine serum (FBS; GIBCO #26140) and 100 U/ml Penicillin/Streptomycin (Invitrogen #15140) and grown at 37 C and 5% CO 2 . Cells were split every 3-4 days. The mouse primary fibroblasts were obtained from mouse dermal tissue following a method published by (Seluanov et al., 2010) . Mouse and human primary fibroblast were maintained in MEM (GIBCO #11095) supplemented with 15% fetal bovine serum, 2% EAA (GIBCO #11130), 2% NEAA (GIBCO #11140), 1% vitamins (GIBCO #11120), 100 U/ml Penicillin/Streptomycin and pH7.4 and grown at 37 C and 5% CO 2 . Cells were split every 3-4 days.
For FISH, cells were plated at 2.5x10 5 cells per dish on 35 mm glass bottom dishes (MatTek #P35G-1.5-10-C) pre-coated for one hour with poly-L-lysine (Sigma #P4707). Unless stated otherwise, the FISH procedure was performed at 2 days post-plating.
Conversion of Fibroblasts into Neuron-like Cells
The trans-differentiation of human primary fibroblasts into fibroblast-derived neurons was performed following the detailed protocol developed by (Richner et al., 2015) . Briefly, the lentiviral cocktail of rtTA, pTight-9-124-BclxL, CTIP2, MYT1L, DLX1 and DLX2 was added to fibroblasts for 16 h, then cells were washed in PBS and cultured in fibroblasts medium (FM) containing 1 mg/mL doxycycline (DOX). At post-induction day (PID) 3, cells were cultured in FM containing 3 mg/mL puromycin, 3 mg/mL blasticidin and DOX. At PID 5 cells were replated onto sterile 24-wells glass-bottom plates (MatTek #P24G-1.5-10-F) pre-coated with polyornithine, fibronectin and laminin and cultured in FM + DOX. On PID 6, FM was replaced by Reprogramming Neuronal Medium (RNM): NbActiv4 (Brainbits #Nb4-500) with 200 mM dibutyl cyclic AMP, 1 mM valproic acid, 10 ng/mL BDNF, 10 ng/mL NT-3 and 1 mM retinoic acid, supplemented with DOX. Half-volume medium changes with RNM were performed every 4 days with addition of DOX every 2 days thereafter until PID 30-35. Addition of puromycin and blasticidin was terminated after PID 14.
Preparation of Primary Neurons
Primary cortical neurons were prepared and maintained as described in . The procedure was performed using sterile standard dissection tools.
Primary cortical neurons were isolated from E16-17 mouse embryos of wild-type FVB/NJ mice. Pregnant females were anesthetized by intraperitoneal injection of Avertin at 250 mg per kg body weight (Sigma, #T48402) followed by cervical dislocation. Embryos were removed and transferred to ice-cold DMEM/F12 medium (Invitrogen #11320). Brains were removed and meninges were carefully detached. Cortices were isolated and transferred into pre-warmed papain solution for 25 min at 37 C, 5% CO 2 to dissolve the tissue. Papain (Worthington #54N15251) was dissolved in 2 mL Hibernate E (Brainbits #HE) and 1 mL EBSS (Worthington #LK003188), and supplemented with 0.25 mL of 10 mg/ml DNase1 (Worthington #54M15168) in Hibernate E. After the 25-30 min incubation, the papain solution was gently removed and 1 mL NbActiv4 (Brainbits #Nb4-500) supplemented with 2.5% FBS was added to the tissue. Tissues were then dissociated by gentle trituration through a fire-polished, glass Pasteur pipet. Neurons were counted, diluted at 1 3 10 6 cells/ml and plated as required for each experiment as described below. After overnight incubation at 37 C, 5% CO 2 , an equal volume of NbActiv4 supplemented with anti-mitotics, 2.4 mg/ml 5-Fluoro-2 0 -deoxyuridine monophosphate (Sigma #F3503) and 4.8 mg/ml Uridine triphosphate (Sigma #U6625) to prevent the growth of non-neuronal cells, was added to neuronal cultures. Half of the volume of media was replaced with fresh NbActiv4 containing anti-mitotics every 48 hours until the experiments were performed. FISH experiments 2 3 10 5 cells were plated in the glass center of 35 mm glass-bottom dishes (MatTek #P35G-1.5-10-C) pre-coated with poly-L-lysine (Sigma #P4707). Cells were fixed and processed for FISH five days post-preparation.
In vitro silencing and cell viability assays 1 3 10 5 neurons per well were plated on 96-well plates pre-coated with poly-L-lysine (BD BIOCOAT #356515) as described in . Cells were processed 7 days post-treatment.
RT-qPCR
Experiments were performed with 2x10 6 cortical primary neurons plated on 6 cm plates, pre-coated with poly-D-lysine.
Oligonucleotides
Sequences and chemical modification patterns of siRNA HTT and ASO HTT are described in Table S2 . All siRNAs design, synthesis and quality control have been performed in house and are available upon request. ASOs, designed by IONIS Pharmaceuticals (Hung and Leeds, 2007) , have been purchased from Exiqon.
RNA Polymerase II Inhibition
Triptolide was dissolved in DMSO to a 10 mM stock concentration. Primary cortical neurons were treated with a final concentration of 25 mM triptolide (MedChemExpress #HY-32735) for indicated amount of time. Cells were fixed directly after treatment and processed for FISH experiment.
Cell Viability Assay
The oligonucleotide cytotoxicity was assessed in vitro in primary neurons in 96-well plates using alamarBlueâ reagent (Life Technologies #DAL1025) as recommended by manufacturer instruction. Briefly, 20 ml of alamarBlueâ reagent were added in 200 ml primary neurons culture medium and incubated for 4 hours. Resofurin fluorescence was measured at 550 nm excitation and 600 nm emission wavelengths.
Animal Stereotaxic Injections of Oligonucleotides
All mice used were wild-type female adults FVB/NJ, 14 weeks old at the time of the injection (The Jackson Laboratory). Prior to injection, mice were deeply anesthetized with 1.2% Avertin (Sigma #T48402). 4 nmol DHA-siRNA NTC , DHA-siRNA HTT , ASO NTC or ASO HTT (n = 3 mice per treatment group), diluted at 2 nmol/ml in aCSF, were administered by direct bollus microinjection into the right striatum by stereotaxic placement; coordinates (relative to bregma) were +1.0 mm anterio-posterior, +2.0 mm medio-lateral, and +3.0 mm dorso-ventral. All injection surgeries were performed using sterile surgical techniques and were accomplished using standard rodent stereotaxic instrument and an automated microinjection syringe pump (Digital Mouse Stereotaxic Frame; World Precision Instrument #504926). Mice were euthanized 7 days post-injection and brains were harvested.
Preparation of Mouse Brain Sections
Mice were sacrificed according to our institutional IAUCUC protocol (#A2411). Brains were removed, placed with eye bulbs facing upward in disposable cryomold (Polysciences, inc #18986-1), and frozen in O.C.T. embedding medium (Tissue-Tek #4583) in a dry ice/methanol bath. Brains were stored in À80 C and transferred at À20 C 24 hours prior sectioning. Brains were sliced into 20 mm brain sections using a cryostat (temperatures: sample holder À13 C, blade À12 C) (ThermoFisher CryoStar NX70) and mounted on superfrost slides (Fisher #1255015). Slides were stored at À80 C until further experiment.
Fluorescent In Situ Hybridization FISH allows to perform single-cell detection of transcripts in situ and accurately quantify and report the relative levels of mRNA expression. Therefore, we compared the expression level of Htt mRNA with the expression level of housekeeping genes rather than normalize Htt mRNA level with any other control gene. mRNAs vary in sequence and length which may affect their subcellular localization. Thus, we investigated the cellular distribution of Htt mRNA with multiple transcripts: 1) the conventional housekeeping mRNAs ActB, Ppib and Hprt; 2) Herc2 mRNA, selected because it is a transcript longer than Htt mRNA; 3) Neat1 and Malat1 long non-coding RNAs (lncRNAs) exclusively localized in the nucleus. The comparison of Htt mRNA level with multiple genes provided a more accurate and unbiased analysis of Htt transcript subcellular localization. See ''Key Resources Table' ' for the detailed list and description of the genes assessed in this study.
Sample preparation
Cultured adherent cells were prepared as described by the manufacturer protocol for cultured adherent cells. Briefly, cells were fixed in 10% formalin for 20-30 min at 4 C and washed three times in PBS. Cells were dehydrated by sequential incubation in 50%, 70% and 100% ethanol for 1 min and incubated at least overnight and up to 6 months in 100% ethanol at À20 C. The day of FISH experiment, cells were re-hydrated by sequential incubation in 70% and 50% ethanol for 1 min followed by incubation in PBS for 10 min. Cells were incubated for 10 min in protease solution (Pretreat III) at room temperature. Cells were washed twice in PBS and processed for FISH.
Brain sections obtained on a cryostat were prepared as described by the manufacturer protocol for fresh frozen tissue (ACDBio #320513). Briefly, sections were fixed in 10% formalin for 15-20 min at 4 C and washed three times in PBS. Sections were dehydrated by sequential incubation in 50%, 70% and 100% ethanol for 5 min at room temperature and air-dried for 5 min at room temperature.
